Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

7,565JPY
22 Mar 2019
Change (% chg)

¥-1,500 (-16.55%)
Prev Close
¥9,065
Open
¥7,565
Day's High
¥7,565
Day's Low
¥7,565
Volume
134,100
Avg. Vol
802,851
52-wk High
¥11,490
52-wk Low
¥6,554

Select another date:

Fri, Mar 22 2019

Photo

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Nikkei falls as financials drag; Eisai indicated to dive

TOKYO, March 22 Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

TOKYO Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab.

Biogen, Eisai scrap Alzheimer drug trials

March 21 Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

Select another date: